Paper Details

  1. Home
  2. Paper Details

Effectiveness and safety of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia within a therapeutic program in Poland: Preliminary multicenter data.

Author: BobrowskaBeata, Borowiec-WolnaJustyna, ChlebusKrzysztof, ChmaraMagdalena, CybulskaBarbara, DobrowolskiPiotr, GałąskaRafał, Gilis-MalinowskaNatasza, GruchałaMarcin, KwapiszewskaAleksandra, MałeckiMaciej, PajkowskiMarcin, Rajtar-SalwaRenata, Romanowska-KocejkoMarzena, StróżykAneta, Waluś-MiarkaMałgorzata, ZdrojewskiTomasz, Żarczyńska-BuchowieckaMarta

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This study assessed the efficacy and safety of alirocumab and evolocumab in patients with heterozygous familial hypercholesterolemia (FH) in Poland. Treatment with PCSK9 inhibitors resulted in a significant decrease in LDL-C levels after 3 months and 1 year of therapy. The most common adverse effects were flu-like symptoms, injection site reactions, fatigue, and musculoskeletal symptoms. PCSK9 inhibitors were highly effective in reducing LDL-C levels in FH patients, but further research is needed to assess their long-term safety and effectiveness.
Paper Details　
Original Abstract of the Article :
BACKGROUND: In Poland, treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has become available free of charge in a therapeutic program. Assessed herein, is the efficacy and safety of alirocumab and evolocumab in patients with heterozygous familial hypercholesterolemia (F...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890405/

データ提供：米国国立医学図書館（NLM）

PCSK9 Inhibitors: A New Hope for Familial Hypercholesterolemia

Familial hypercholesterolemia (FH), a genetic condition characterized by high cholesterol levels, poses a significant risk of heart disease. This research investigates the efficacy and safety of PCSK9 inhibitors, a new class of drugs, in treating FH patients in Poland.

A Breakthrough in Cholesterol Management

The researchers found that PCSK9 inhibitors effectively reduced LDL-C levels in FH patients, providing a significant improvement in cholesterol management. They also reported a favorable safety profile, with the most common side effects being mild and manageable. The research suggests that PCSK9 inhibitors offer a promising treatment option for FH patients who have not responded well to other therapies.

Empowering Patients: Taking Control of Cholesterol

This research highlights the importance of early diagnosis and effective treatment for FH. Patients with FH should consult with their doctor to discuss treatment options and develop a personalized plan to manage their cholesterol levels. PCSK9 inhibitors offer a new avenue for controlling cholesterol and reducing the risk of heart disease.

Dr. Camel's Conclusion

PCSK9 inhibitors are like a refreshing spring in a desert of high cholesterol. They help lower LDL-C levels, offering a new path to heart health for individuals with FH. While further research is needed to fully understand their long-term effects, this research provides a beacon of hope for individuals struggling with this challenging condition.
Date :
  1. Date Completed 2022-04-08
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

35146730

DOI: Digital Object Identifier

PMC8890405

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.